XILIO THERAPEUTICS INC's ticker is and the CUSIP is 98422T100. A total of 32 filers reported holding XILIO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $293,839 | -21.5% | 139,260 | -2.5% | 0.00% | 0.0% |
Q2 2023 | $374,398 | -17.6% | 142,900 | 0.0% | 0.00% | -33.3% |
Q1 2023 | $454,422 | +18.2% | 142,900 | 0.0% | 0.00% | +50.0% |
Q4 2022 | $384,401 | -7.6% | 142,900 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $416,000 | -0.2% | 142,900 | 0.0% | 0.00% | -66.7% |
Q2 2022 | $417,000 | – | 142,900 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RiverVest Venture Management LLC | 1,441,444 | $3,041,447 | 7.52% |
Trustees of Columbia University in the City of New York | 249,635 | $526,730 | 0.97% |
Atlas Venture Life Science Advisors, LLC | 2,759,344 | $5,822,216 | 0.90% |
Octagon Capital Advisors LP | 2,318,500 | $4,892,035 | 0.75% |
Bain Capital Life Sciences Investors, LLC | 2,805,413 | $5,919,421 | 0.66% |
HARVARD MANAGEMENT CO INC | 416,059 | $878 | 0.10% |
Rock Springs Capital Management LP | 1,440,759 | $3,040,001 | 0.08% |
Soleus Capital Management, L.P. | 226,941 | $478,846 | 0.04% |
Artal Group S.A. | 450,000 | $950 | 0.04% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 110,481 | $233,115 | 0.01% |